On Behalf of BioRestorative Therapies Inc. Hey there,
Mesoblast is the name most biotech investors recognize when it comes to stem cell therapies for back pain.
But what if I told you a rival exists — with stronger early data, a faster regulatory track, and zero reliance on donor tissue?
It’s true. This microcap has a therapy already in a pivotal Phase 2 trial… showing huge improvement in pain and mobility for nearly 70% of patients from a single injection.
Even better? The FDA awarded it Fast Track status — a green light few companies ever receive.
And here’s the kicker: while an approved company like Mesoblast trades at a $1.46 billion valuation…
This company trades at just $12 million.
That’s a 114x discount — despite clinical, manufacturing, and IP advantages.
Analysts are starting to wake up. The chart’s forming a breakout wedge.
And with a float under 5 million shares, the next move could be pivotal. 👉 Get the name and symbol before Wall Street catches on
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
This message is a paid advertisement for BioRestorative Therapies Inc. (BRTX ) from Market Jar Media Inc. Wealthpire, Inc. has received a fixed fee of $2,500 from BioRestorative Therapies Inc. (BRTX ) for multiple Dedicated Email Sends, and Newsletter Sponsorships. Other than the compensation received for this advertisement sent to subscribers, Wealthpire, Inc. and its principals are not affiliated with either BioRestorative Therapies Inc. (BRTX ) or Market Jar Media Inc. Wealthpire, Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Wealthpire, Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Wealthpire, Inc. to buy or sell any security. Wealthpire, Inc. has not evaluated the accuracy of any claims made in this advertisement. Wealthpire, Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioRestorative Therapies Inc. (BRTX ) on Market Jar Media Inc. website for additional information about the relationship between Market Jar Media Inc. and BioRestorative Therapies Inc. (BRTX ). |